Anticipate the forces that will shape your oncology market
Tumor Worlds™ combines social science, oncology fluency, and commercialization strategy to reveal the cognitive and structural forces shaping adoption across 30+ tumor types.
Why Tumor Worlds™?
Every Tumor World has its own decision ecosystem.
Tumor Worlds™ helps commercial teams build those differences into strategy from day one.
Tumor Worlds™ Launch
Tumor Worlds™ launches in NSCLC, with prostate and pancreatic cancers next, and additional tumor types to follow through 2026.
Available Now:
NSCLCComing Soon:
Prostate Cancer Pancreatic CancerBy the end of 2026:
Acute Myeloid Leukemia Colorectal Cancer Breast CancerWant to join the waitlist for upcoming indications?
Join WaitlistDon't see your indication on the list? Submit a request for your tumor type.
Submit a RequestThe Problem
Evidence Alone Doesn't Change Practice
Positive Phase 3 data is necessary but often insufficient to change clinical practice. Physicians don't adopt new therapies based on evidence alone. They interpret new data through the realities of the disease space: established treatment paradigms, biomarker infrastructure, clinical workflow, peer influence, perceived risk, and the practical consequences of changing practice.
These dynamics differ across tumor types. Every Tumor World has its own decision ecosystem—with distinct evidence expectations, treatment norms, operational realities, and barriers to change. What accelerates adoption in one setting may create resistance in another.
Commercial teams need a way to understand those dynamics before they appear in prescribing data—and incorporate that intelligence into strategy from day one.
How Tumor Worlds™ Works
Tumor Worlds™ draws on analysis across 30+ tumor types to identify the cognitive and structural forces shaping adoption in each tumor type.
Tumor Worlds™ turns complex market dynamics into actionable strategic guidance.
What You'll Get:
Four suites that deliver one integrated view of your market.
World Dynamics
The clinical, competitive, and structural context shaping each tumor market.
Treater Insights
The roles, influence patterns, and physician segments shaping adoption.
Cognitive Insights
The mindsets and decision patterns shaping treatment choices.
Lifecycle Intelligence
Strategic guidance for navigating risk and opportunity across the asset lifecycle.
What Tumor Worlds™ Helps You Do
Understand the clinical, competitive, and structural forces shaping how change happens in your market.
Understand who influences change, how authority flows, and where different physician groups require different strategies.
Translate insight into strategic priorities, risk flags, and resource decisions across the asset lifecycle.
Who Tumor Worlds™ is Built For
Ready to decode your Tumor World™?
Connect with our Oncology Center of Excellence to learn more.
Schedule a Discovery callThe Team Behind Tumor Worlds™
Tumor Worlds™ was developed by a team of oncology strategists, behavioral scientists, and innovation leaders who understand what it takes to move brands forward in a complex therapeutic landscape.
Meredith Jacobetz, PhD
Senior Director, Oncology Center of Excellence
With over 15 years in strategic commercial insights within pharma, Meredith Jacobetz, PhD, leads BioVid's Oncology Center of Excellence. She specializes in oncology product strategy and commercialization, drawing on both client-side and supplier-side experience to help brands reach their full potential. Meredith holds a PhD in Oncology from the University of Cambridge.
LinkedIn
Gregg Quy
Senior Director, Behavioral Insights & Strategy
Gregg Quy is a Research Psychologist with 18+ years of global pharma and healthcare research experience. As Senior Director in BioVid's Cognitive Insights team, he decodes the biases and emotional drivers shaping how patients and HCPs navigate treatment decisions. A registered psychologist with fieldwork across 30+ countries, Gregg translates cognitive science into strategy that moves brands forward, and is a recognized voice at conferences including EPHMRA and Intellus.
LinkedIn
Sal Zerilli, PhD
Executive Director, Knowledge & Innovation
Sal Zerilli, PhD, is a Social Psychologist and Psychotherapist with 17 years of experience in insight and strategy work for pharmaceutical companies. As Executive Director of Knowledge & Innovation, he ensures BioVid's work draws on leading thinking across the social sciences and design, bringing deep fieldwork experience across 50+ disease states to crack complex behavioral codes for clients.
LinkedIn